FDA lets pharmacies compound neonatal starter nutrition without patient specific prescriptions for 180 days
After two outsourcing facilities that made standardized neonatal starter parenteral nutrition announced permanent shutdowns, FDA issued an immediately effective guidance on September 4, 2026 describing what it will not enforce, for which products, under which conditions, until March 8, 2027.
FDA's guidance, Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates, was issued September 4, 2026 and noticed in the Federal Register on September 9. For 180 days, until March 8, 2027, FDA does not intend to act against a state licensed pharmacy or federal facility that compounds the starter parenteral nutrition products listed in the guidance's Appendix A for hospitals without patient specific prescriptions, if every listed condition is met.
For 503B outsourcing facilities, FDA likewise does not intend to act on the use of a bulk substance not otherwise permitted under section 503B(a)(2)(A), or on certain stability and dating shortfalls, provided the facility uses a default beyond use date of no more than 30 hours at room temperature and 9 days refrigerated, with further conditions that depend on whether an aggregate batch exceeds 5,000 units. FDA says it may extend, modify or withdraw the policy.
- Hospital and health system 503A pharmacies asked to supply neonatal units.
- 503B outsourcing facilities that take on the discontinued products.
Narrow by design: hospital and health system pharmacies and outsourcing facilities supplying neonatal starter parenteral nutrition. It does not extend to any other product.
| Source published | September 4, 2026 | FDA press announcement; guidance immediately in effect. |
|---|---|---|
| Effective | September 9, 2026 | Federal Register notice of availability. |
| Expires | March 8, 2027 | The temporary policy runs 180 days from publication. |
This is what an FDA shortage accommodation actually looks like: a named product list, explicit conditions, a start date and an end date, in a published guidance. A compounder that cites a supply gap to justify compounding anything else without a patient specific prescription is outside this policy, and the contrast with the GLP-1 shortage list fight is instructive.
- If you supply a neonatal unit, read Appendix A and the conditions before compounding under this policy, and tell your state board.
- If you do not, note the shape of the policy and do not read it as permission for anything beyond its list.
- Diary March 8, 2027; the policy ends unless FDA extends it.
Compounding (503A and 503B). The Compounding domain covers 503A and 503B status and the conditions under which products may be compounded. This policy is a bounded, dated exception to the usual conditions.
- FDA Takes Steps to Maintain Newborn Access to Life-Saving Starter Nutrition Products PrimaryU.S. Food and Drug AdministrationRetrieved Sep 22, 2026
Press announcement of September 4, 2026.
- Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates; Guidance for Industry PrimaryU.S. Food and Drug AdministrationDocket FDA-2026-D-9571Retrieved Sep 22, 2026
The 180 day policy to March 8, 2027; 503A conditions and Appendix A; 503B beyond use dates and the 5,000 unit batch threshold.
- Federal Register notice of availability, FR Doc. 2026-18368 PrimaryFederal Register via GovInfoFR Doc. 2026-18368Retrieved Sep 22, 2026
Know where your pharmacy stands before the rules change again.
Certified pharmacies are re-verified nightly against state boards, federal enforcement records and their own websites.